Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial
Endoscopy · 01.10.2026 · 58 (10) · 1073-1081
DOI: 10.1055/a-2823-8603 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Endoscopy, erschienen am 01.10.2026. Verfasst von Sanjay R V Gadi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Medicine, North Carolina, United States, Durham. Hauptthemen laut MEDLINE: Argon Plasma Coagulation, Gastric Fundus, Gastric Mucosa, Gastroplasty. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Endoscopic sleeve gastroplasty (ESG) facilitates 13.6%–16.2% total body weight loss (TBWL) at 12 months, but falls short of that seen with surgical vertical sleeve gastrectomy, in part owing to the retention of the gastric fundus. In adults with obesity, gastric fundal mucosal ablation (GFMA) reduces fasting plasma ghrelin (FPG), hunger, cravings, and accommodation. Combined GFMA-ESG could improve TBWL. This study aimed to evaluate the effectiveness and safety of sequential GFMA followed by ESG in adults with obesity, building on previously published 6-month results of GFMA alone. This was a prospective, first-in-human, two-phase clinical trial. Ten participants underwent GFMA, followed by ESG at month 6, and were followed for 12 months post-ESG (18 months total). GFMA was performed using hybrid argon plasma coagulation to lift and ablate the entire gastric fundal mucosa. ESG was performed using standard full-thickness endoscopic suturing of the gastric body. The primary end point was TBWL; secondary end points were safety and changes in FPG, maximum tolerated volume (MTV), and validated appetite questionnaires. Mean TBWL was 22.5% (SD 8.3%) at month 18. Hunger-related behaviors and eating self-efficacy showed sustained improvements. FPG was decreased at month 6 and returned toward baseline by month 18, while MTV remained suppressed. No serious adverse events occurred. Sequential GFMA-ESG is safe and induces substantial weight loss, reduced MTV of ingested nutrients, and improved behavioral measures. This combination approach builds on prior traditional ESG and GFMA-only results and may represent a promising advancement of endoscopic therapeutic options for weight loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke University School of Medicine, Medicine, North Carolina, United States, Durham.
- True You Weight Loss Georgia LLC, Gastroenterology, Georgia, United States, Atlanta.
- Mayo Clinic Minnesota, Division of Gastroenterology and Hepatology, Minnesota, United States, Rochester.
- True You Weight Loss, Gastroenterology, North Carolina, United States, Cary.
- Albany Medical College, School of Medicine, New York, United States, Albany.
- Nova Southeastern University, College of Arts and Sciences, Florida, United States, Fort Lauderdale.
ORCID-Profile: Sanjay R V Gadi, Nader Bakheet
Zitieren
APA
Gadi, S. R. V., Maselli, D. B., Donnangelo, L. L., Wooley, C., Comer, T., Casey, S., Jain, A., Jain, A., Chapman, C. G., Bakheet, N., Badurdeen, D., Kumbhari, V., & McGowan, C. E. (2026). Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial. Endoscopy, 58(10), 1073-1081. https://doi.org/10.1055/a-2823-8603
Vancouver
Gadi SRV, Maselli DB, Donnangelo LL, Wooley C, Comer T, Casey S, et al. Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial. Endoscopy. 2026;58(10):1073-1081. doi:10.1055/a-2823-8603
BibTeX
@article{Gadi2026,
author = {Gadi, Sanjay R V and Maselli, Daniel B and Donnangelo, Lauren L and Wooley, Chase and Comer, Taylor and Casey, Shannon and Jain, Aryan and Jain, Aditya and Chapman, Christopher G and Bakheet, Nader and Badurdeen, Dilhana and Kumbhari, Vivek and McGowan, Christopher E},
title = {Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {10},
pages = {1073--1081},
doi = {10.1055/a-2823-8603}
}
EUVIMED